ICMT抗体;ICMT Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P13099(ICMT Antibody) at dilution 1/45. (Original magnification: ×200)    

  
  

**Background of ICMT Antibodies**

ICMT (isoprenylcysteine carboxyl methyltransferase) is a critical enzyme involved in post-translational modification of proteins, particularly those containing C-terminal CaaX motifs, such as Ras superfamily GTPases. By catalyzing the carboxyl methylation of prenylated cysteine residues, ICMT facilitates proper membrane localization and function of these proteins, which play essential roles in cell signaling, proliferation, and survival. Dysregulation of ICMT activity has been linked to cancer, neurodegenerative disorders, and cardiovascular diseases, making it a potential therapeutic target.

Antibodies targeting ICMT are vital tools for studying its expression, localization, and mechanistic roles in health and disease. They enable detection of ICMT in various experimental models (e.g., Western blot, immunofluorescence) and aid in validating its interaction with substrates or inhibitors. Research using ICMT antibodies has revealed its overexpression in certain cancers, correlating with poor prognosis, and highlighted its role in modulating Ras-driven oncogenesis. Additionally, these antibodies support drug discovery efforts by assessing ICMT inhibition in preclinical studies.

Despite their utility, developing specific ICMT antibodies remains challenging due to the enzyme’s conserved regions and low abundance. Recent advances in monoclonal antibody technology and epitope mapping have improved specificity, enhancing their application in both basic research and translational studies. Understanding ICMT’s biology through these antibodies continues to uncover its therapeutic potential in precision medicine.